Profile | GDS2987 / GI_31343330-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 5.7 | 15 |
GSM215253 | HMVEC_vehicle_rep3 | 5.5 | 19 |
GSM215254 | HMVEC_atorvastatin_rep1 | 17.3 | 42 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | 7.7 | 19 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 27.4 | 47 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 44 | 62 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 16.8 | 50 |
GSM215295 | HMVEC_SLx2119_rep2 | 12 | 24 |
GSM215296 | HMVEC_SLx2119_rep3 | 2.2 | 4 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 0.1 | 0 |
GSM215310 | PASMC_vehicle_rep3 | 32.7 | 47 |
GSM215311 | PASMC_atorvastatin_rep1 | 24.8 | 40 |
GSM215312 | PASMC_atorvastatin_rep2 | 13.3 | 21 |
GSM215313 | PASMC_atorvastatin_rep3 | 10.1 | 15 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 26.8 | 42 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 15.5 | 29 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 8.9 | 16 |
GSM215328 | PASMC_SLx2119_rep2 | 3.4 | 7 |
GSM215329 | PASMC_SLx2119_rep3 | 21.1 | 38 |
GSM215330 | Fibroblasts_vehicle_rep1 | 31.4 | 56 |
GSM215331 | Fibroblasts_vehicle_rep2 | 8.1 | 23 |
GSM215332 | Fibroblasts_vehicle_rep3 | 2.4 | 8 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 14.7 | 37 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 1.7 | 5 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 3.2 | 8 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 11.2 | 35 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 1 | 3 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 39.6 | 65 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 29.8 | 61 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 14.4 | 38 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 7.8 | 20 |